Natural products with antileprotic activity

Revista Brasileira de Farmacognosia

Volumn 17, Issue 1, 2007, Pages 141-148

  Barbosa Filho, José M ^a   Do Nascimento Júnior, Francisco A ^a   De Andrade Tomaz, Anna Cláudia ^a   De Athayde Filho, Petrônio F ^a   Da Silva, Marcelo S ^a   Da Cunha, Emídio V Leitão ^a   De De Souza, Maria F Vanderlei ^a   Batista, Leõnia M ^a   Diniz, Margareth F F Melo ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Hansen's disease; Lepra; Leprosy; Medicinal plants; Mycobacterium leprae; Natural products; Revision

Indexed keywords

EID: 34047161456     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2007000100022     Document Type: Article

References (63)

1. Almeida RN, Navarro DS, Barbosa-Filho JM 2001. Plants with central analgesic activity Phytomedicine 8: 310-322.
2. Amaral FMM, Ribeiro MNS, Barbosa-Filho JM, Reis AS, Nascimento FRF, Macedo RO 2006. Plants and chemical constituents with giardicidal activity. Rev Bras Farmacogn 16(Supl.): 696-720.
3. Anthony JP, Fyfe L, Smith H 2005. Plant active components - a resource for antiparasitic agents? Trends Parasitol 21:462-468.
4. Barbosa-Filho JM, Vasconcelos THC, Alencar AA, Batista LM, Oliveira RAG, Guedes DN, Falcão HS, Moura MD, Diniz MFFM, Modesto-Filho J 2005. Plants and their active constituents from South, Central, and North America with hypoglycemic activity. Rev Bras Farmacogn 15: 392-413.
5. Barbosa-Filho JM, Piuvezam MR, Moura MD, Silva MS, Lima KVB, Cunha EVL, Fechine IM, Takemura OS 2006a. Anti-inflammatory activity of alkaloids: A twenty century review. Rev Bras Farmacogn 16: 109-139.
6. Barbosa-Filho JM, Medeiros KCP, Diniz MFFM, Batista LM, Athayde-Filho PF, Silva MS, Cunha EVL, Almeida JRGS, Quintans-Júnior LJ 2006b. Natural products inhibitors of the enzyme acetylcholinesterase. Rev Bras Farmacogn 16: 258-285.
7. Barbosa-Filho JM, Martins VKM, Rabelo LA, Moura MD, Suva MS, Cunha EVL, Souza MFV, Almeida RN, Medeiros IA 2006c. Natural products inhibitors of the angiotensin converting enzyme (ACE). A review between 1980-2000. Rev Bras Farmacogn 16: 421-446.
8. Boiteau P, Batsimamanga AR 1956. Asiaticoside extracted from Centella asiatica, it's therapeutic uses in healing of experimental refractory wounds, leprosy, skin tuberculosis and lupus. Therapie 11: 125-149.
9. Chaudhuri S, Ghosh S, Chakraborty I, Kundu S, Hazra SK 1978. Use of a common Indian herb "Mandukaparni" in the treatment of leprosy. J Indian Med Ass 70: 177-180.
10. Cowan MM 1999. Plants products as antimicrobial agents. Clin Microbiol Rev 12: 564-582.
11. Deps PD, Guedes BVS, Bucker Filho J, Andreatta MK, Marcari RS, Rodrigues LC 2006. Characteristics of known leprosy contact in a high endemic area in Brazil. Lepr Rev 77: 34-40.
12. Eidt LM 2004. Breve historia da hansenfase: sua expansão do mundo para as Américas, o Brasil e o Rio Grande do Sul e sua trajetória na saúde pública brasileira. Saúde e Sociedade 13: 76-88.
13. Faes JT 1966. Hospitales de leprosos en Asturias durante las edades media y moderna. Oviedo, [s.n.].
14. Falcão HS, Lima IO, Santos VL, Dantas HF, Diniz MFFM, Barbosa-Filho JM, Batista LM 2005. Review of the plants with anti-inflammatory activity studied in Brazil. Rev Bras Farmacogn 15: 381-391.
15. Franzblau SG, Biswas AN, Harris EB 1992. Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae. Antimicrob Agents Chemoth 36: 92-94.
16. Gertrude PC, Bernadette YGI, Virginia EC, Jocelyn BL, Claribel LJ, Manuela LRP 1994. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Ch 38: 515-517.
17. Gilani AH, Rahman A 2005. Trends in ethnopharmacology. J Ethnopharmacol 100: 43-49.
18. Goncalves JG 1941. A introdução e a aclimaçã o de plantas contra a lepra. São Paulo - Brasil.
19. Gonçalves MCR, Moura LSA, Rabelo LA, Barbosa-Filho JM, Cruz HMM, Cruz J 2000. Produtos naturals inibidores da enzima HMG CoA redutase. Rev Bras Farm 81: 63-71.
20. Greenwood D 1988. Fusidic acid. In P. K. Peterson and J. Verhoef (ed.), Antimicrobial agents annual 3. Elsevier Science Publishers BV, Amsterdam.
21. Gupta PN 1981. Antileprotic action of an extract from "Anantamul" (Hemidesmus indicus) Leprosy in India 53: 354-359.
22. Gurib-Fakim A 2006. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med 27: 1-93.
23. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S 1999. Curcumim causes the growth arrest and apoptosis of B cell lymphoma by downregulation of EGR-1, C-MYC, BCL-XL, NF-KB, and P53. Clin Immunol 93: 152-161.
24. Hansen GHA 2007. Who named it? www.whonamedit.com/doctor.cfm/596.html. Accessed in January 28th, 2006.
25. Hastings RC, Richard VR, Jacobson RR 1984. Ansamycin activity against rifampicin-resistant Mycobacterium leprae. Lancet. 8386: 1130.
26. Holzhey M, Roth HH, Hoepfner V1992. Use of Allicin-urotopin as internal drug for the treatment of infections and cancer. Patent-Ger Offen-4,024,155.
27. Ji B, Perani EG, Petinom C, Grosset JH 1996. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemoth 40: 393-399.
28. Kataria HC 1994. Medicinal plant Melia azedarach used in leprosy control. Orient J Chem 10:178-180.
29. Lee KH, Chung H, Lee CW, Chung CH 1992. Antitumor and immunostimulating proteoglycan G009 manufacture with ganoderma. Patent-Pet Int Appl-92,10,562.
30. Lepra 2004. Manual Merck de saúde para a família. www.manualmerck.net/artigos/imprime.asp?id=208&cn=1715. Accessed in January 28th, 2006.
31. Levy L 1975. The activity of chaulmoogra acids against Mycobacterium leprae. Amer Rev Respir Dis 111: 703.
32. McCoy GW 1942. Chaulmoogra oil in the treatment of leprosy. Pub Health Rep 57:1727-1733.
33. Mester de Parajd L, Balakrishnan S, Saint-Andre P, Mester de Parajd M 1982. Deoxyfructo-serotonin: A new drug with anti-leprosy activity. Ann Microbiol 133B: 427-432.
34. Miralles J, Pares Y 1980. Fatty acid composition of some oils from Senegalese seeds. Revue Francaise des Corps Gras 27: 393-396.
35. Morais LCSL, Barbosa-Filho JM, Almeida RN 2003. Plants and bioactives compounds for the treatment of Parkinson's desease. Arquivo de Fitomedicina 1: 127-132.
36. Moura MD, Torres AR, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM 2001. Natural products inhibitors of models of mammary neoplasia. Brit J Phytotherapy 5: 124-145.
37. Moura MD, Silva JS, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM 2002. Natural products reported as potential inhibitors of uterine cervical neoplasia. Acta Farm Bonaerense 21: 67-74.
38. Murty GK 1974. Clinical toxicity study of Semecarpus anacardium. Indian J Exp Biol 12: 444-446.
39. Natsuhara Y, Oka S, Kaneda K, Kato Y, Yano I 1990. Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships. Cancer Immunol Immunother 31: 99-106.
40. Nowak K, Surylo P 2006. Antileprosy drugs. Wiadomosci Chemiczne 60: 257-278.
41. Ojha D, Singh G 1968. Apamarga (Achyranthes aspera) in the treatment of lepromatous lepra. Lepr Rev. 39:23.
42. Ojha D, Singh G, Upadhyaya YN 1969. Clinical evaluation of Acacia catechu, Willd. (Khadira) in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 37: 302-307.
43. Parascandola J 1998. Miracle at Carville: The introduction of the sulfones for the treatment of leprosy. Pharm Hist 40: 59-66.
44. Pereira JV, Modesto-Filho J, Agra MF, Barbosa-Filho JM 2002. Plant and plant-derived compounds employed in prevention of the osteoporosis. Acta Farm Bonaerense 27: 223-234.
45. Pinto AC, Silva DHS, Bolzani VS, Lopes NP, Epifanio RA 2002. Current status challenges and trends on natural products in Brazil. Quim Nova 25: 45-61.
46. Possolo H 1941. As flaucortiáceas antilepróticas. Monografia do Laboratório Químico-Farmacêutico do Instituto "Conde de Lara".Rio de Janeiro.
47. Pupo JA 1926. Tratamento especifico da lepra pelo óleo de chaulmoogra e seus derivados - estudo das flacourtiaceas do Brasil. Publicação do Brasil-Médico, Sodré Ed., Rio de Janeiro.
48. Ramos Jr AN, Heukelbach J, Gomide M, Hinders DC, Schleuder PAM 2006. Health systems research training as a tool for more effective Hansen's disease control programmes in Brazil. Lepr Rev 77: 175-188.
49. Rocha LG, Almeida JRGS, Macedo RO, Barbosa-Filho JM 2005. Areview of natural products with antileishmanial activity. Phytomedicine 12: 514-535.
50. Rotlier R 1951. Treatment of leprosy by a Smilax species. Maroc Med 30: 776-780.
51. Santos Filho L 1960. Medicina colonial. In H Sérgio Buarque (org.) História da civilização brasileira. DIFEL, São Paulo.
52. Saxena VK 1993. Novel 4-phenyl coumarin glycoside: a potential antileprotic drug from Dalbergia latifolia seeds. Journal of the Institution of Chemists 65: 161-162.
53. Scott GF, Diana LW, Thomas PG, Rally FC, Gertrude PC, Bernadette YGI, Virginia EC, Jocelyn BL, Claribel LJ, Manuela LRP 1994. Clinical trial of fusidic acid for lepromatous leprosy. Antimicrobial Agents Chemoth 38: 1651-1654.
54. Shepard CC, Levy L, Fasal P 1974. Further experience with the rapid bactericidal effects of rifampin on Mycobacterium leprae. Amer J Trop Med Hyg 23: 1120-1124.
55. Silva JS, Moura MD, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM 2003. Natural products inhibitors of ovarian neoplasia. Phytomedicine 10:221-232.
56. Sousa-Araújo HC 1956. História da lepra no Brasil; 1500-1952. Departamento da Imprensa Nacional, Rio de Janeiro.
57. Stein S 1963. Alone No Longer: The Story of a Man who Refused to Be One of the Living Dead. New York: Funk and Wagnalls, pp. 38-39.
58. Tubery PR 1969. Glycosidic extract of Lasiosiphon kraussianus useful as an antileprous medicament. Patent-Fr M-7333.
59. Waters MF, Rees RJ, Pearson JM, Laing AB, Helmy HS, Gelber RH 1978. Rifampicin for lepromatous leprosy: nine years' experience. Brit Med J 1(6106):133-136.
60. WHO 2000. The final push towards elimination of leprosy: strategic plan, 2000-2005. www.paho.org/common/Display.asp?Lang=E&RecID=7211. Accessed in January 28th, 2006.
61. WHO 2006. Leprosy situation in the WHO Region of the Americas. www.who.int/lep/situation/americas/en/print.html. Accessed in January 28th, 2006.
62. Xu R, Fidler JM, Musser JH 2005. Bioactive compounds from Tripterygium wilfordii. In Studies in natural products chemistry. v. 32, Bioactive natural products (Part L) Publisher, Elsevier.
63. Yunes RA, Calixto JB 2001. Plantas medicinais sob a ótica da química medicinal moderna. Chapecó: Argos, 500p.